Tradestie Institutional Equity Comparison Engine

AQST vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Momentum & Technical, Options & Structure while AQST counters with relative strength in Growth & Margin. Fundamentally, AQST trades at N/M Forward P/E with -114.1% operating margin (-41.0% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
AQST N/M vs MNOV 8.5x Fwd P/E
Growth & Margin Winner AQST
Op Margin -114.1% vs -1232.2% ยท YoY -41.0% vs +12.4%
Momentum & Technical Winner MNOV
1Y -40.6% vs -8.4% ยท 52W Pos 14% vs 3%
Options & Structure Winner MNOV
BREAKDOWN (64th %ile IV) vs UNCLASSIFIED (50th %ile IV)
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
1M Return -16.22%
1Y Return -40.65%
Forward P/E N/M
Unified AI Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AQST -40.65% MNOV -8.39% Spread: +32.26 pp (MNOV Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period AQST Revenue MNOV Revenue AQST Op. Margin MNOV Op. Margin Margin Edge
FY2018 $70M N/A -72.6% N/A AQST
FY2019 $50M N/A -100.1% N/A AQST
FY2020 $50M N/A -93.6% N/A AQST
FY2021 $50M $0M -68.2% -253.0% AQST
FY2022 $50M N/A -88.2% N/A AQST
FY2023 $50M $0M -29.9% -990.0% AQST
FY2024 $60M N/A -53.5% N/A AQST
FY2025 $40M $0M -159.5% -3242.5% AQST

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AQST (5) vs MNOV (5)
Institutional Metric AQST MNOV Criterion Row Winner
Market Capitalization Scale $465.7M $65.1M Larger Scale AQST
Trailing P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY) Growth -41.0% +12.4% Higher Growth MNOV
Operating Margin (TTM) Profitability -114.1% -1232.2% Higher Margin AQST
Net Profit Margin Profitability -162.3% 0.0% Higher Margin MNOV
Return on Equity (ROE) Capital Efficiency 0.0% -24.8% Higher ROE AQST
52-Week Range Position Momentum 14% ($3โ€“$7) 3% ($1โ€“$4) Stronger Trend AQST
Beta / 30D Volatility Risk Regime 0.89ฮฒ ยท 56% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 62.9 / 100 (BUY) 50.2 / 100 (HOLD) Higher Composite AQST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AQST vs MNOV Buy Guide
AQST BREAKDOWN
61d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live AQST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AQST nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.